Termination of aconitine-induced atrial fibrillation by the KACh-channel blocker tertiapin: Underlying electrophysiological mechanism

Journal of Pharmacological Sciences

Volumn 125, Issue 4, 2014, Pages 406-414

  Suzuki, Kazumasa ^a   Matsumoto, Akio ^a   Nishida, Hirofumi ^a   Reien, Yoshie ^a   Maruyama, Hiroo ^a   Nakaya, Haruaki ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Acetylcholine receptor operated K+channel; Aconitine; Atrial fibrillation; Tertiapin

Indexed keywords

ACETYLCHOLINE RECEPTOR OPERATED POTASSIUM ION CHANNEL; ACONITINE; ANTIARRHYTHMIC AGENT; CARBACHOL; PILSICAINIDE; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; SODIUM ION; TERTIAPIN; UNCLASSIFIED DRUG; BEE VENOM; SODIUM;

ACTION POTENTIAL DURATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ELECTRIC POTENTIAL; ELECTROCARDIOGRAM; ELECTROSTIMULATION; HEART ATRIUM FIBRILLATION; HEART AUTOMATICITY; HEART CONDUCTION; HEART ELECTROPHYSIOLOGY; HEART EXCITATION; HEART MUSCLE CELL; HEART MUSCLE FIBER MEMBRANE STEADY POTENTIAL; HEART MUSCLE POTENTIAL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; INTRACELLULAR MEMBRANE; MEMBRANE CURRENT; NERVE BLOCK; NONHUMAN; SINUS RHYTHM; WHOLE CELL PATCH CLAMP; ANIMAL; ATRIAL FIBRILLATION; CELL CULTURE; CHEMICALLY INDUCED; CHRONIC DISEASE; CYTOLOGY; DISEASE MODEL; DOG; DRUG EFFECTS; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGY; GUINEA PIG; HEART ATRIUM; MEMBRANE POTENTIAL; METABOLISM; MOLECULARLY TARGETED THERAPY; PHYSIOLOGY;

ACONITINE; ANIMALS; ATRIAL FIBRILLATION; BEE VENOMS; CELLS, CULTURED; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; DOGS; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGICAL PHENOMENA; GUINEA PIGS; HEART ATRIA; IN VITRO TECHNIQUES; MEMBRANE POTENTIALS; MOLECULAR TARGETED THERAPY; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; SODIUM;

EID: 84906960532     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.14023FP     Document Type: Article

References (29)

1. Kunze DL, Lacerda AE, Wilson DL, Brown AM. Cardiac Na currents and the inactivating, reopening, and waiting properties of single cardiac Na channels. J Gen Physiol. 1985; 86: 691-719.
2. Wang SY, Wang GK. Voltage-gated sodium channels as primary targets of diverse lipid-soluble neurotoxins. Cell Signal. 2003; 15: 151-159.
3. +ions. J Physiol. 2002; 538: 759-771.
4. Coumel P. 1996. Autonomic influences in atrial tachyarrhythmias. J Cardiovasc Electrophysiol. 1996; 7: 999-1007.
5. Kr-blocker dofetilide. J Cardiovasc Pharmacol. 2008; 51: 162-169.
6. +channel blocker on experimental atrial fibrillation. Circ Arrhythm Electrophysiol. 2011; 4: 94-102.
7. +channels. Biochemistry. 1998; 37: 13291-13299.
8. +channels in rabbit cardiac myocytes. J Pharmacol Exp Ther. 2000; 293: 196-205.
9. KAChin acetylcholine-induced atrioventricular blocks. Br J Pharmacol. 2000; 131: 569-577.
10. KAChblocker, terminates atrial fibrillation with selective atrial effective refractory period prolongation. Pharmacol Res. 2006; 54: 136-141.
11. Nakaya H, Furusawa Y, Ogura T, Tamagawa M, Uemura H. Inhibitory effects of JTV-519, a novel cardioprotective drug, on potassium currents and experimental atrial fibrillation in guinea pig hearts. Br J Pharmacol. 2000; 131: 1363-1372.
12. Hashimoto K, Ishii M, Komori S, Mitsuhashi H. Canine digitalis arrhythmia as a model for detecting Na-channel blocking antiarrhythmic drugs: a comparative study using other canine arrhythmia models and the new antiarrhythmic drugs, propafe-none, tocainide, and SUN 1165. Heart Vessels. 1985; 1: 29-35.
13. Inomata N, Ohno T, Ishihara T, Akaike N. Antiarrhythmic agents act differently on the activation phase of the ACh-response in guinea-pig atrial myocytes. Br J Pharmacol. 1993; 108: 111-115.
14. Levi AJ, Dallon GR, Hancox JC, Mitcheson JS, Issberner J, Bates JA, et al. Role of intracellular sodium overload in the genesis of cardiac arrhythmias. J Cardiovasc Electrophysiol. 1997; 8: 700-721.
15. Wright SN 2001. Irreversible block of human heart (hH1) sodium channels by the plant alkaloid lappaconitine. Mol Pharmacol. 2001; 59: 183-192.
16. Sawanobori T, Hirano Y, Hiraoka M. Effect of acetylcholine on aconitine induced delayed afterdepolarisation in the frog atrium and ventricle. Cardiovasc Res. 1987; 21: 804-812.
17. 2+on aconitine-induced arrhythmias. Jpn Heart J. 1996; 37: 709-718.
18. +channel in heart. Nature. 1987; 325: 321-326.
19. +channel by a G-protein-independent mechanism. J Gen Physiol. 1996; 108: 381-391.
20. +ions depends on the presence of phosphatidylinositol phosphates. Proc Natl Acad Sci U S A. 1998; 95: 1307-1312.
21. 2+ions. J Gen Physiol. 1999; 114: 673-684.
22. Buchanan JW Jr, Saito T, Gettes LS. The effects of antiarrhythmic drugs, stimulation frequency, and potassium-induced resting membrane potential changes on conduction velocity and dV/dtmax in guinea pig myocardium. Circ Res. 1985; 56: 696-703.
23. Nygren A, Giles WR. Mathematical simulation of slowing of cardiac conduction velocity by elevated extracellular. Ann Biomed Eng. 2000; 28: 951-957.
24. Veeraraghavan R, Poelzing S. Mechanisms underlying increased right ventricular conduction sensitivity to flecainide challenge. Cardiovasc Res. 2008; 77: 749-756.
25. Takahara A, Takeda K, Tsuneoka Y, Hagiwara M, Namekata I, Tanaka H. Electrophysiological effects of the class Ic antiarrhythmic drug pilsicainide on the guinea-pig pulmonary vein myocardium. J Pharmacol Sci. 2012; 118: 506-511.
26. Gaspo R, Bosch RF, Talajic M, Nattel S. Functional mechanisms underlying tachycardia-induced sustained atrial fibrillation in a chronic dog model. Circulation. 1997; 96: 4027-4035.
27. Morillo CA, Klein GJ, Jones DL, Guiraudon CM. Chronic rapid atrial pacing. Structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation. Circulation. 1995; 91: 1588-1595.
28. K,AChsingle-channel activity with atrial tachycardia remodelling in canine atrial cardiomyocytes. Cardiovasc Res. 2008; 77: 35-43.
29. K,AChis constitutively active in patients with chronic atrial fibrillation. Circulation. 2005; 112: 3697-3706.